Abstract Clinical practice guidelines recommend yearly surveillance mammography for breast cancer survivors, yet many women do not receive this service. The objective of this study was to evaluate factors related to long-term surveillance mammography adherence among breast cancer survivors. We conducted a retrospective cohort study among women C18 years, diagnosed with incident stage I or II breast cancer between 1990 and 2008. We used medical record and administrative health plan data to ascertain covariates and receipt of surveillance mammography for up to 10 years after completing breast cancer treatment. Surveillance included post-diagnosis screening exams among asymptomatic women. We used multivariable repeated measures generalized estimating equation regression models to estimate odds ratios and robust 95 % confidence intervals to examine factors related to the annual receipt of surveillance mammography. The analysis included 3,965 women followed for a median of six surveillance years; 79 % received surveillance mammograms in year 1 but decreased to 63 % in year 10. In multivariable analyses, women, who were\40 years or 80? years of age (compared to 50-59 years), current smokers, had greater comorbidity, were diagnosed more recently, had stage II cancer, or were treated with mastectomy or breast conserving surgery without radiation, were less likely than other women to receive surveillance mammography. Women with outpatient visits during the year to primary care providers, oncologists, or both were more likely to undergo surveillance. In this large cohort study of women diagnosed with early-stage invasive breast cancer, we found that important subgroups of women are at high risk for non-adherence to surveillance recommendations, even among younger breast cancer survivors. Efforts should be undertaken to actively engage breast cancer survivors in managing long-term surveillance care.
Introduction
In the US, breast cancer is the most frequently diagnosed cancer in women, with more than 200,000 new cases diagnosed each year [1] . There are an estimated 2.8 million breast cancer survivors living in the US today [1] at risk for recurrence and second primary breast tumors. Regular surveillance mammography among breast cancer survivors reduces breast cancer mortality [2] , possibly because the second breast cancer events (SBCE) are diagnosed at earlier stages with more favorable prognoses [2] . This reinforces the importance of long-term survivorship care and emphasizes the need for understanding utilization of mammography among survivors.
National guidelines recommend yearly mammographic evaluation for breast cancer survivors [3, 4] , yet many women do not undergo surveillance mammography [5] [6] [7] [8] [9] . One study reported surveillance rates of 82.1 % in the year following breast cancer treatment, which declined to 68.5 % by year 4 among women 65 years or older diagnosed with early-stage invasive breast cancer [5] . Several factors are associated with the lower rates of mammography use in breast cancer survivors, including advanced age, racial/ethnic minority status, higher stage of disease, and receipt of breast-conserving surgery without radiation [5, 7, [9] [10] [11] . Women with outpatient visits to primary care physicians or oncologists during follow-up are more likely to receive surveillance [5, 10, 11] . However, most studies examining factors related to surveillance mammography have focused on older breast cancer survivors [5, [9] [10] [11] or were limited by relatively short follow-up [5, [9] [10] [11] and incomplete ascertainment of surveillance procedures [7] . While the risk of recurrence is highest within the first 3-5 years post-diagnosis [12, 13] , SBCEs can occur at any time. Thus, it is important to understand the patterns of surveillance mammography for a more extended follow-up period. This study has the longest follow-up to date to evaluate factors associated with surveillance mammography among women of all ages diagnosed with early-stage invasive breast cancer.
Materials and methods

Study population
The parent study, COmmonly Used Medications and Breast Cancer Outcomes (COMBO) [14] , was conducted within Group Health Cooperative (GH), a nonprofit integrated delivery system in western Washington State and parts of Idaho. GH is located within the reporting region of the western Washington Cancer Surveillance System, a population-based cancer Surveillance, Epidemiology, and End Results (SEER) registry [1] . COMBO included women who were C18 years of age, diagnosed with a histologically confirmed incident stage I or II [15] breast cancer between 1990 and 2008, and enrolled for at least 1 year before and after (unless died) the initial breast cancer diagnosis. Women were eligible if they were alive and recurrence free for 120 days after completing surgery for the incident breast cancer [16, 17] , giving a sample of 4,216 women. The study was approved by the GH Institutional Review Board.
Data collection
Data were collected from 1 year prior to breast cancer diagnosis through the earliest of death, disenrollment from GH (lapse in membership of 90? days), or end of study (i.e., date of chart abstraction) [18] . Data were collected from medical record review (paper and electronic), SEER, health plan automated administrative databases, and GH's Breast Cancer Screening Recruitment and Reminder (BSRR) survey [19] . GH's automated databases include demographics, smoking status, enrollment, inpatient and outpatient encounters including all breast services [20] , results of breast services, pharmacy dispensings, and death [21] . We collected information on primary definitive surgery, chemotherapy, radiation treatment, and outcomes (i.e., recurrence and second primaries) from medical records. Cancer registry data included year of diagnosis, American Joint Committee on Cancer (AJCC) stage [15] at diagnosis, lymph node status, hormone receptor status, and tumor size.
Surveillance procedures
We considered the first 6 months post-diagnosis as the treatment period and excluded all the surveillance procedures performed during this time [7, 9, 10] . We evaluated the following sequential 12-month intervals after diagnosis: months 7-18 (year 1), 19-30 (year 2), 31-42 (year 3), 43-54 (year 4), 55-66 (year 5), 67-78 (year 6), 79-90 (year 7), 91-102 (year 8), 103-114 (year 9), and 115-126 (year 10).
Procedures such as blood chemistry tests or bone scans in asymptomatic women to look for distant recurrence are not recommended [3, 4] . Our outcome included surveillance procedures for local SBCEs, which included asymptomatic mammographic and breast MRI exams. We ascertained exam date and indication designated by the interpreting radiologist from GH administrative databases (1996 forward) and medical charts (prior to 1996). We only included surveillance procedures post-diagnosis where the patient reported no symptoms at the time of the exam and the indication was designated as screening [2, 22] . Surveillance procedures also included all short-interval follow-up (SIFU) exams unless the SIFU took place \9 months after a diagnostic exam [2, 22] . A woman was categorized as having received at least one surveillance procedure (yes/no) within each surveillance year. Only 0.7 % of surveillance procedures were breast MRI exams; therefore, we refer to surveillance procedures as surveillance mammography.
Covariates
We measured and defined 3 types of covariates: (1) static covariates assessed only once either at pre-diagnosis, diagnosis, or during treatment and remained fixed over time; (2) covariates updated each surveillance year were repeatedly assessed during each of the ten surveillance years (i.e., variable status did not carry over to the subsequent years); and (3) time-varying covariates assessed throughout the entire study period and varied over time when status changed (i.e., variable status carried over to the subsequent years) (Fig. 1) .
Static covariates
We considered the following covariates static: menopausal status, body mass index (BMI), smoking status, breast cancer characteristics (diagnosis year, stage [15] , and hormone receptor status), and breast cancer treatment including primary surgery (breast conserving or mastectomy) and radiation therapy (Fig. 1a) . BMI was calculated from the weight and height ascertained from the medical record during the year before diagnosis. If menopausal status was missing or unknown (19 %) at diagnosis, we characterized a woman as peri-or pre-menopausal if she was \55 years of age and post-menopausal if she was C55 years of age [23] .
Covariates updated each surveillance year
We calculated the current age by adding 1 year to the age at diagnosis for each sequential surveillance year (Fig. 1b) . We captured the type of provider seen (primary care or oncology) during outpatient visits for each surveillance year.
Time-varying covariates
Charlson comorbidity index score (0, 1, 2?) was calculated using diagnoses for comorbid conditions captured 12 months before the breast cancer diagnosis and also assessed annually post-diagnosis for changes in score (Fig. 1c) [24] . Women were only allowed to move from lower to higher Charlson scores (e.g., 0 to 1). For multivariable analyses, we used repeated measures generalized estimating equation (GEE) regression models to estimate odds ratios (ORs) and robust 95 % confidence intervals (CIs). A logit link based on a binomial distribution with an unstructured correlation covariance was implemented. The GEE method accounts for the correlation among the repeated observations for each subject while also adjusting for different numbers of observations across individuals [25] .
Subjects were censored at the earliest of death, disenrollment, diagnosis of a SBCE, or 10 years after breast cancer treatment. SBCE was defined as any ductal carcinoma in situ or invasive breast cancers of the ipsilateral (recurrence) or contralateral (second primary) breast or in any regional or distant sites [26] . To ensure women had the opportunity to receive surveillance in a given surveillance year, we required subjects to have complete data for that entire surveillance year (i.e., subjects must be alive and not censored). Of the 4,216 women in our sample, we excluded 251 because they did not complete the entire year 1 surveillance interval (108 SBCEs, 66 deaths, 28 end of study, and 14 disenrolled), resulting in a final analytic cohort of 3,965 women.
The primary multivariable analysis examined the association between select characteristics and receipt of yearly surveillance mammography over time. The characteristics consisted of known and suspected factors associated with surveillance [5, [7] [8] [9] [10] [11] 27] : age, diagnosis year, years of follow-up after treatment, stage [15] , hormone receptor status, primary treatment, BMI, smoking status, type of provider seen, menopausal status, and Charlson score. In a subgroup analysis, we stratified the results by age at diagnosis of incident breast cancer (\50, 50-64, and 65? years).
We evaluated the sensitivity of results by excluding the year prior to death, SBCE, or diagnosis of other cancers (including all diagnoses of cancer other than breast) to address the possibility that any differences we observed were influenced by these events. Mode of initial breast cancer detection affects receipt of surveillance mammography [28] ; therefore, in secondary analyses, we added the initial mode of detection (screen-detected, screen intervaldetected, diagnostic-detected, and diagnostic intervaldetected) to our multivariable model. To compare our results with the previous surveillance studies, we repeated analyses in women 65? years of age at diagnosis and included only 4 years of follow-up. All analyses were performed using Stata/IC 12 software (StataCorp LP, College Station, TX, USA).
Results
Patient characteristics
The majority of women were Caucasian (89 %), postmenopausal (73 %), non-smokers (86 %), had normal BMI (18.5-24.9 kg/m 2 ) (34 %), and no comorbidities (77 %) at diagnosis. The mean age at diagnosis was 62.6 years; the majority of cancers was stage I (64 %), ER?/PR? (69 %), and treated with breast-conserving surgery plus radiation (52 %). Receipt of surveillance During year 1, 79 % of women received surveillance mammography. Receipt of surveillance declined through year 6 to 68 % and then became relatively stable at 63-66 % in years 7-10 ( Fig. 2) . The median number of surveillance mammograms per patient over the 10-year follow-up was 4 [interquartile range (IQR) [2] [3] [4] [5] [6] .
The number of women remaining in each surveillance year are available in Appendix A. Overall, there were 3,044 (77 %) women censored during the 10-year followup period (409 SBCEs, 473 deaths, 1,542 end of study, and 620 disenrolled). A total of 2,836 (72 %) contributed to four surveillance years and 1,298 (33 %) contributed to eight surveillance years. The median number of surveillance years per patient was 6 (IQR 3-9). Median surveillance years among women who experienced a SBCE were 3 (IQR 1-5) or died during follow-up were 4 (IQR 2-7).
Factors related to receipt of surveillance
The unadjusted results indicate that women who received surveillance mammography in year 1 were slightly younger and non-smokers compared to women not receiving surveillance (Table 1) . Women diagnosed with earlier stage breast cancers that were screen-detected, lymph node negative, smaller tumor size, and treated with breast-conserving surgery plus radiation were more likely to undergo surveillance mammography in year 1 (all P \ 0.05). Women diagnosed more recently and those with the initial cancers tested for HER-2 were less likely to receive surveillance. Characteristics by the subsequent surveillance years are available in Appendix A; patterns of mammography use did not change appreciably from year 1. However, receipt of surveillance in the subsequent years was higher among women with Charlson scores of 0 versus 1? and initial cancers treated with endocrine therapy versus no treatment.
In adjusted analyses, surveillance declined with increasing years of follow-up (Table 2 ). Compared to women 50-59 years of age, those aged\40 years or 80? years had lower odds of receiving surveillance mammography. Current smokers and women with more comorbidities had lower odds of receiving mammography, independent of age. Women with outpatient visits to primary care providers, oncologists, or both had higher odds of undergoing surveillance than women seeing neither type of provider. Characteristics of the initial breast cancer were also associated with receipt of surveillance mammography. Women diagnosed more recently, those with stage II cancer (significant only for stage IIA) and those who received mastectomy or breast-conserving surgery without radiation had lower odds of receiving surveillance compared to the respective referent groups of earlier diagnosis years, stage I, and breast-conserving surgery plus radiation. In secondary adjusted analyses, we found that women initially diagnosed with breast cancer following an asymptomatic screening mammogram had higher odds of surveillance mammography (OR = 1.31, 95 % CI 1.15-1.50) compared to women diagnostic-detected. In adjusted analyses stratified by age, we observed similar patterns of surveillance mammography use between the age strata, though not all characteristics associated with receipt of surveillance in the unstratified analysis remained statistically significant (Table 3) . Peri-or pre-menopausal women \50 and 50-64 years at diagnosis demonstrated lower odds of receiving surveillance mammography compared to post-menopausal women in their respective age strata. There was suggestion that among women \50 years of age at diagnosis, current and past smokers (vs. never smokers) and those with stage II cancer had higher odds of undergoing surveillance mammography, though CIs included 1.0.
Discussion
Guidelines recommend yearly mammography for breast cancer survivors [3, 4] , yet many survivors do not undergo annual surveillance mammography [5-7, 9, 11] with declining adherence over time [5, 11, 27] . We observed clear associations between patient characteristics such as smoking, more comorbidities, ages \40 or 80?, later stage at diagnosis, and treatment with mastectomy or breastconserving surgery without radiation and underutilization of surveillance. Receipt of surveillance mammograms steadily declined in our study population with each year following the initial diagnosis, yet our surveillance rates at comparable follow-up times were generally higher over time than those reported previously. Our study population was younger compared to the earlier studies and younger women had higher rates of surveillance over time. Similar to our study results, another study found that surveillance mammography rates among women 65 years or older diagnosed with early-stage invasive breast cancer were 82.1 % in year 1 but dropped off to 68.5 % within 4 years of completing cancer treatment [5] . Similar patterns were observed in another study of breast cancer survivors age 55 years and older [11] . Onega et al. found slightly higher rates, though 18-month intervals were used instead of 12-month intervals [27] . Women aged 65 and older demonstrated surveillance mammography rates of 89.3 % at 24 months post-diagnosis and rates remained high at 81.5 % at 78 months post-diagnosis [27] . We are the only study to date that evaluated surveillance patterns among breast cancer survivors of all ages, followed for up to 10 years since completion of the initial treatment.
Several prior studies examined determinants to explain variability in receipt of surveillance over time [5, 10, 11, 27] . Similar to our findings, factors consistently associated with lower rates of surveillance include advanced age, higher stage of disease, and receipt of breast-conserving surgery without radiation [5, 7, [9] [10] [11] , whereas women with outpatient visits to primary care physicians and oncologists during follow-up are more likely to receive surveillance mammography [5, 10, 11] . Prior studies report that women with high comorbidity burden are less likely to receive surveillance mammograms [10, 11] . This is supported by our finding that women with higher Charlson scores were less likely to receive surveillance compared to women with no comorbidities. This may be related to the ''sick stopper effect'' whereby patients who become increasingly ill, with a greater number of competing comorbidities, forego preventive care [10, 29] . Women with breast cancers initially identified by screening while asymptomatic (screen-detected) are more likely to undergo surveillance mammography compared to those diagnosed once symptoms develop (diagnostic-detected) [28] . Our findings from secondary analyses support that women initially diagnosed with screendetected cancers were more likely to undergo surveillance mammography during follow-up. No prior studies have evaluated surveillance patterns among women\40 years of age. We determined that women \40 years had lower rates of surveillance during follow-up. These women were more likely to have diagnostic-detected, stage II initial cancers compared to women[40 years, both of which are associated with reduced receipt of surveillance mammograms after diagnosis [5, 7, 10, 11, 27, 28] . When we restricted our analyses to women 65? years at diagnosis and included only the first 4 years after completion of treatment, our findings were similar to those reported previously [5, 10, 11, 27] . In our study, we had access to complete longitudinal data on surveillance mammograms for up to 10 years, which is unavailable in most research settings. We were able to evaluate patient symptoms reported at the time of the mammographic exam as well as the indication designated by the radiologist to differentiate surveillance from diagnostic exams [20] . GH's automated databases, link to SEER, and medical charts provide detailed and unbiased access to medical information on demographics, breast cancer characteristics, treatment, medical encounters, comorbidities, SBCEs, and surveillance history and allowed for timevarying adjustment of covariates. We evaluated a large, covered population with stable membership, minimal copays and co-insurance for preventive services such as mammography, and who receive almost all of their care within the system.
Our study is not without limitations. We evaluated a single health plan with an insured population with access to complete medical care so estimates may be lower in populations with less access to medical services or the uninsured. The majority of our population was White (89 %) with no comorbidities (77 %) at diagnosis of the incident breast cancer. Our findings may not be generalizable to women who are African American or those with comorbid medical conditions, where receipt of surveillance is likely lower [10, 11] . Our results predominantly pertain to surveillance mammography and rates may be different for other modalities such as MRI. We did not exclude women who had prophylactic mastectomy after their initial breast cancer diagnosis so our surveillance rates may be underestimated since these women are not recommended for surveillance mammography. However, we estimate this to be\1 % of women in our study. Contrary to Keating et al. [10] , we found that women diagnosed more recently were less likely to undergo surveillance, despite adjusting for years of follow-up. It is possible that more mammograms are classified as diagnostic rather than screening, even if for surveillance, in more recent years. Follow-up care intensity and decision about whether to seek preventive services such as mammography is complex. We did not capture provider recommendations, patient beliefs, or patient attitudes regarding follow-up care, nor could we assess why women choose not to receive surveillance care. Furthermore, we did not address when to stop undergoing surveillance and we did not identify subgroups of women who appropriately may not benefit from continued surveillance because of competing comorbid conditions or poor prognosis. We did, however, censor on SBCE because receipt of surveillance may dramatically change with the diagnosis of a SBCE. Censoring women who develop a SBCE minimizes misclassification of diagnostic or treatment-related imaging as a surveillance procedure. In summary, yearly surveillance mammography declines over time after the initial early-stage cancer treatment. Our results suggest that factors influencing receipt of surveillance mammography among breast cancer survivors include: age, stage and treatment of the initial breast cancer, smoking status, comorbidity, and contact with primary care and oncologists. These findings were consistent across different age strata and reinforce the need for active engagement of all breast cancer survivors in long-term follow-up care, especially among women at the highest risk for non-adherence to surveillance recommendations. Our findings can be used to help identify women at the highest risk for non-adherence to surveillance recommendations which can inform researchers and providers about where efforts are most needed to improve surveillance adherence. Further research is needed to better understand patient attitudes and behaviors toward survivorship care, with an emphasis on surveillance.
